Vivo Capital LLC acquired a new stake in shares of Uniqure NV (NASDAQ:QURE) during the 1st quarter, HoldingsChannel.com reports. The institutional investor acquired 180,336 shares of the biotechnology company’s stock, valued at approximately $10,757,000. Uniqure makes up 1.1% of Vivo Capital LLC’s portfolio, making the stock its 23rd biggest holding.
A number of other hedge funds have also modified their holdings of the stock. Harvest Group Wealth Management LLC purchased a new position in shares of Uniqure during the 1st quarter worth approximately $26,000. Advisor Group Inc. boosted its position in shares of Uniqure by 5.3% during the 4th quarter. Advisor Group Inc. now owns 9,966 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 502 shares in the last quarter. Pearl River Capital LLC bought a new position in shares of Uniqure during the 1st quarter valued at about $32,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in shares of Uniqure by 14.7% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,045 shares of the biotechnology company’s stock valued at $301,000 after purchasing an additional 648 shares in the last quarter. Finally, Legal & General Group Plc boosted its position in shares of Uniqure by 264.2% during the 4th quarter. Legal & General Group Plc now owns 965 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 700 shares in the last quarter. 60.12% of the stock is currently owned by institutional investors.
Several equities analysts have recently weighed in on the stock. Janney Montgomery Scott restated a “buy” rating on shares of Uniqure in a research report on Tuesday. BidaskClub upgraded Uniqure from a “sell” rating to a “hold” rating in a report on Tuesday, May 21st. Cantor Fitzgerald set a $81.00 price target on Uniqure and gave the company a “buy” rating in a report on Friday, May 10th. SunTrust Banks increased their price target on Uniqure to $76.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. Finally, Piper Jaffray Companies initiated coverage on Uniqure in a report on Friday, April 12th. They set an “overweight” rating and a $80.00 price target on the stock. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $75.82.
In related news, insider Christian Klemt sold 1,546 shares of the firm’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $57.18, for a total value of $88,400.28. Following the completion of the transaction, the insider now directly owns 54,539 shares of the company’s stock, valued at $3,118,540.02. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Matthew C. Kapusta sold 8,000 shares of the firm’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $58.38, for a total value of $467,040.00. Following the completion of the transaction, the chief executive officer now directly owns 421,730 shares of the company’s stock, valued at $24,620,597.40. The disclosure for this sale can be found here. In the last 90 days, insiders sold 88,922 shares of company stock worth $5,605,629. 2.91% of the stock is currently owned by corporate insiders.
Shares of Uniqure stock traded up $4.46 during midday trading on Wednesday, hitting $70.43. The company had a trading volume of 830,181 shares, compared to its average volume of 548,771. The company has a market cap of $2.83 billion, a price-to-earnings ratio of -30.10 and a beta of 0.95. The company has a current ratio of 9.51, a quick ratio of 9.51 and a debt-to-equity ratio of 0.38. Uniqure NV has a 1-year low of $21.98 and a 1-year high of $78.02.
Uniqure (NASDAQ:QURE) last announced its quarterly earnings data on Monday, April 29th. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.03). The company had revenue of $1.14 million during the quarter, compared to analyst estimates of $2.00 million. Uniqure had a negative return on equity of 48.90% and a negative net margin of 1,032.06%. As a group, research analysts forecast that Uniqure NV will post -3.01 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://www.dispatchtribunal.com/2019/06/12/vivo-capital-llc-acquires-shares-of-180336-uniqure-nv-nasdaqqure.html.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
See Also: How much money do you need to begin day trading?
Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Uniqure NV (NASDAQ:QURE).
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.